Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT04478266
Registration number
NCT04478266
Ethics application status
Date submitted
10/07/2020
Date registered
20/07/2020
Date last updated
8/12/2023
Titles & IDs
Public title
Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer
Query!
Scientific title
A Randomized, Multicenter, Double-blind Phase 3 Study of Amcenestrant (SAR439859) Plus Palbociclib Versus Letrozole Plus Palbociclib for the Treatment of Patients With ER (+), HER2 (-) Breast Cancer Who Have Not Received Prior Systemic Anti-cancer Treatment for Advanced Disease
Query!
Secondary ID [1]
0
0
2020-001824-33
Query!
Secondary ID [2]
0
0
EFC15935
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
AMEERA-5
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Amcenestrant-matching placebo
Treatment: Drugs - SAR439859
Treatment: Drugs - Palbociclib
Treatment: Drugs - Letrozole
Treatment: Drugs - Goserelin
Treatment: Drugs - Letrozole-matching placebo
Active Comparator: Letrozole + Palbociclib - Participants received letrozole 2.5 milligrams (mg) capsule along with amcenestrant-matching placebo once daily, continuously and palbociclib 125 mg orally (PO), once daily (QD) from Day 1 to Day 21 of each 28-day treatment cycle until disease progression, death or study cut-off date, whichever comes first (maximum exposure: 112 weeks). Goserelin once every 4 weeks in pre/peri menopausal women and men.
Experimental: Amcenestrant + Palbociclib - Participants received amcenestrant 200 mg tablet along with letrozole-matching placebo once daily, continuously and palbociclib 125 mg PO, QD from Day 1 to Day 21 of each 28-day treatment cycle until disease progression, death, or study cut-off date, whichever comes first (maximum exposure: 109 weeks). Goserelin once every 4 weeks in pre/peri menopausal women and men.
Treatment: Drugs: Amcenestrant-matching placebo
Pharmaceutical form: Tablets Route of Administration: Oral
Treatment: Drugs: SAR439859
Pharmaceutical form: Tablets Route of Administration: Oral
Treatment: Drugs: Palbociclib
Pharmaceutical form: Capsules/Tablets Route of Administration: Oral
Treatment: Drugs: Letrozole
Pharmaceutical form: Capsules Route of Administration: Orally
Treatment: Drugs: Goserelin
Pharmaceutical form: Depot Injection Route of Administration: Subcutaneous
Treatment: Drugs: Letrozole-matching placebo
Pharmaceutical form: Capsules Route of Administration: Orally
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Progression-free Survival (PFS)
Query!
Assessment method [1]
0
0
PFS was defined as the time interval (in months) from the date of randomization to the date of first documented tumor progression as per Response Evaluation Criteria in Solid Tumors (RECIST 1.1) assessed by local radiologist or investigator, or death (due to any cause), whichever comes first. Progressive Disease (PD) as per RECIST 1.1: at least a 20 percent (%) increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [1]
0
0
From randomization to the date of first documented tumor progression or death due to any cause or data cut-off date whichever comes first (maximum duration: 81 weeks)
Query!
Secondary outcome [1]
0
0
Overall Survival (OS)
Query!
Assessment method [1]
0
0
OS was defined as the interval (in months) from the date of randomization to the date of documented death (due to any cause). In the absence of observation of death, survival time was censored to last date the participant was known to be alive or at the cut-off date, whichever comes first. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [1]
0
0
From randomization to the death due to any cause or data cut-off date, whichever comes first (maximum duration: 81 weeks)
Query!
Secondary outcome [2]
0
0
12-month Progression-free Survival (PFS) Rate
Query!
Assessment method [2]
0
0
Percentage of participants who were disease progression-free at Month 12 after randomization were reported in this outcome measure. PFS was defined as the time interval (in months) from the date of randomization to the date of first documented tumor progression as per RECIST 1.1 assessed by local radiologist or investigator, or death (due to any cause), whichever comes first. PD as per RECIST 1.1: at least a 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. The PFS rate at Month 12 was estimated using the Kaplan-Meier method and provided an estimation of the percentage of participants who were disease progression-free at Month 12 after randomization.
Query!
Timepoint [2]
0
0
Month 12
Query!
Secondary outcome [3]
0
0
Percentage of Participants With Objective Response
Query!
Assessment method [3]
0
0
Objective response was defined as percentage of participants having a partial response (PR) or complete response (CR) according to the RECIST version 1.1 assessed by investigator. As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to less than (<) 10 millimeters (mm). PR was defined as at least a 30%decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters.
Query!
Timepoint [3]
0
0
From randomization to the date of first documented tumor progression, death due to any cause or data cut-off date whichever comes first (maximum duration: 81 weeks)
Query!
Secondary outcome [4]
0
0
Duration of Response (DOR)
Query!
Assessment method [4]
0
0
DOR was defined as time (in months) from first documented evidence of CR or PR until disease progression determined by investigator as per RECIST 1.1, or start of any anti-cancer therapy, or death from any cause, whichever occurs first. For participants with ongoing response at the time of the analysis, DOR was censored at the date of the last valid disease assessment not showing documented progression performed before the initiation of a new anticancer treatment (if any). As per RECIST 1.1, CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the Baseline sum diameters. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [4]
0
0
From the date of first response of CR or PR until disease progression or death, or start of any anti-cancer therapy or data cut-off date, whichever comes first (maximum duration: 81 weeks)
Query!
Secondary outcome [5]
0
0
Percentage of Participants With Clinical Benefit
Query!
Assessment method [5]
0
0
Clinical Benefit was defined as the percentage of participants having a confirmed CR, PR, or stable disease (SD) for at least 24 weeks determined by investigator as per RECIST 1.1, from date of randomization until disease progression, or death, or data cut-off date, or initiation of post treatment anti-cancer therapy, whichever occurs first. As per RECIST 1.1; CR was defined as disappearance of all target, non-target lesions & normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to <10 mm. PR: at least a 30% decrease in sum of diameters of target lesions, taking as reference Baseline sum diameters. SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference smallest sum diameters. PD: at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions.
Query!
Timepoint [5]
0
0
From randomization until disease progression, or death, or data cut-off date, whichever comes first (maximum duration: 81 weeks)
Query!
Secondary outcome [6]
0
0
Progression-free Survival on Next Line of Therapy (PFS2)
Query!
Assessment method [6]
0
0
PFS2 was defined as the time interval (in months) from the date of randomization to the date of first documentation of PD on the next systemic anti-cancer therapy according to investigator, or death due to any cause in the absence of documented PD on the next systemic anti-cancer therapy, whichever occurs first. PD was defined as at least 20% increase in sum of diameters of target lesions, unequivocal progression of existing non-target lesions. Analysis was performed by Kaplan-Meier method.
Query!
Timepoint [6]
0
0
From randomization to date first documented disease progression on the next systemic anti-cancer therapy, or death due to any cause, or data cut-off date, whichever comes first (maximum duration: 81 weeks)
Query!
Secondary outcome [7]
0
0
Pharmacokinetics: Plasma Concentrations of Amcenestrant
Query!
Assessment method [7]
0
0
Amcenestrant plasma concentrations at specified time points were reported. Data for this outcome measure was not planned to be collected and analyzed for Letrozole+Palbociclib arm as pre-specified in protocol.
Query!
Timepoint [7]
0
0
Cycle 1 Day 1: 3 hours (hr) post-dose, Cycle 1 Day 15: pre-dose, Cycle 2 Day 1: pre-dose, 3 hr post-dose, Cycle 2 Day 15: pre-dose, Cycle 3 Day 1: pre-dose, Cycle 4 Day 1: pre-dose, Cycle 7 Day 1: pre-dose, Cycle 10 Day 1: pre-dose
Query!
Secondary outcome [8]
0
0
Pharmacokinetics: Plasma Concentrations of Palbociclib
Query!
Assessment method [8]
0
0
Palbociclib plasma concentrations at specified time points were reported.
Query!
Timepoint [8]
0
0
Cycle 1 Day 1: 3 hr post-dose, Cycle 1 Day 15: pre-dose, Cycle 2 Day 1: pre-dose, 3 hr post-dose, Cycle 2 Day 15: pre-dose, Cycle 3 Day 1: pre-dose, Cycle 4 Day 1: pre-dose, Cycle 7 Day 1: pre-dose, Cycle 10 Day 1: pre-dose
Query!
Secondary outcome [9]
0
0
Change From Baseline in European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire (EORTC-QLQ-C30) Domain Scores
Query!
Assessment method [9]
0
0
EORTC-QLQ-C30: cancer-specific instrument with 30 questions for evaluation of new chemotherapy & assessment of participant reported outcome. These include 5 functional scales, 9 symptom scales, & Global Health Status/quality of life scale (GHS/QoL). All 14 items/domains were scored on scale of 1 (not at all) to 4 (very much) & GHS/QoL, scored on scale of 1 (very poor) to 7 (excellent). All scales are transformed from raw scores to linear scales ranging 0 to 100. Higher score for functional & GHS/QoL=higher level of functioning, & higher score for symptoms scales=higher symptom burden. Least Square (LS) mean and Standard Error (SE) were derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect. Average of LS mean change from Baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for each domain was reported in this outcome measure.
Query!
Timepoint [9]
0
0
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
Query!
Secondary outcome [10]
0
0
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Breast Cancer Specific Module (EORTC-QLQ-BR23) Domain Scores
Query!
Assessment method [10]
0
0
QLQ-BR23: disease-specific Health-related QOL assesses breast cancer impact & side effects of treatment. EORTCQLQ- BR23 contains 23 items: multi-item scales & single-item measures. 4 functional scales (body image, sexual functioning, sexual enjoyment, future perspective) & 4 scales related to symptoms of disease or treatment (arm symptoms, breast symptoms, systemic therapy side effects, & upset by hair loss). All items scored 1 (not at all) to 4 (very much). Scores of all scales transformed from raw scores to linear scales ranging 0-100. Higher score for functional scales=better outcome; higher score for symptoms scales=higher symptom burden. LS mean & SE were derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value & stratifications factors as fixed effect. Average of LS mean change from Baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for each domain was reported.
Query!
Timepoint [10]
0
0
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
Query!
Secondary outcome [11]
0
0
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Breast Cancer Specific Module (EORTC QLQ-BR45) Domain Scores
Query!
Assessment method [11]
0
0
EORTC QLQ-BR45: comprised of all 23 items from the QLQ-BR23 plus an additional 22 items assessing endocrine therapy symptoms (10 items), endocrine sexual symptoms (4 items), breast satisfaction (2 items), and skin mucosis symptoms (6 items). All items scored 1 (not at all) to 4 (very much). Scores of all scales transformed from raw scores to linear scales ranging 0 to 100. Higher score for functional scales = better outcome; higher score for symptoms scales = higher symptom burden. LS mean and SE are derived from Mixed Model Repeated Measures (MMRM) model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect. Average of LS mean change from Baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for each domain (endocrine therapy symptoms, endocrine sexual symptoms, breast satisfaction and skin mucosis symptoms) was reported.
Query!
Timepoint [11]
0
0
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
Query!
Secondary outcome [12]
0
0
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Visual Analog Scale (VAS) Score
Query!
Assessment method [12]
0
0
EQ-5D-5L is a standardized measure of health status, provides a simple, generic measure of health for clinical and economic appraisal, and consists of 2 sections: the EQ-5D-5L health state utility index (descriptive system) and the EQ-5D-5L VAS. The Visual Analogue Scale is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. LS mean and SE are derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect. Average of LS mean change from Baseline values of overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for VAS was reported in this outcome measure.
Query!
Timepoint [12]
0
0
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
Query!
Secondary outcome [13]
0
0
Change From Baseline in European Quality of Life Working Group Health Status Measure 5 Dimensions (5D), 5 Levels (5L) (EQ-5D-5L) Score: Health Utility Index Value Score
Query!
Assessment method [13]
0
0
EQ-5D-5L: consists of 2 sections: EQ-5D-5L health state utility index (descriptive system) & VAS. The EQ-5D descriptive system consists of 5 dimensions: mobility, self-care, usual activities, pain/discomfort & anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems, & extreme problems. Response options are measured with 5-point Likert scale (for 5L version). The EQ-5D-5L responses are converted into single index utility score between 0 to 1, where higher score indicates better health state & lower score indicate worse health state. LS mean and SE were derived from MMRM model with change from Baseline values as response variable, treatment, time, treatment-by-time interaction, Baseline value and stratifications factors as fixed effect. Average of LS mean change from Baseline values overall treatment (i.e., each cycle [Cycle 1 up to Cycle 21]) for health utility index value score was reported in this outcome measure.
Query!
Timepoint [13]
0
0
Baseline, overall treatment duration (Cycle 1 up to Cycle 21 [i.e., 81 weeks])
Query!
Secondary outcome [14]
0
0
Time to First Chemotherapy
Query!
Assessment method [14]
0
0
Time to chemotherapy was defined as the time interval (in months) from the date of randomization to the start date of the first chemotherapy after disease progression.
Query!
Timepoint [14]
0
0
From randomization to the start date of the first chemotherapy (maximum duration: 81 weeks)
Query!
Secondary outcome [15]
0
0
Number of Participants With Hematological Abnormalities During the Treatment Period
Query!
Assessment method [15]
0
0
Hematological parameters assessed were anemia, lymphocyte count decreased, neutrophil count decreased, white blood cell decreased, platelet count decreased. Parameters were assessed as per the National Cancer Institute Common Terminology Criteria for Adverse Experience version 5.0 (NCI-CTCAE v 5.0), where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Treatment period was defined as the time from the first dose of study treatments up to 30 days after last dose of study treatment.
Query!
Timepoint [15]
0
0
From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 112 weeks)
Query!
Secondary outcome [16]
0
0
Number of Participants With Liver Function Abnormalities of Grade 3 and 4 During the Treatment Period
Query!
Assessment method [16]
0
0
Liver Function parameters assessed were aspartate aminotransferase increased, alanine aminotransferase increased, alkaline phosphatase increased, total bilirubin increased, gamma-glutamyl transferase increased. Parameters were assessed as per the NCI-CTCAE v 5.0, where Grade 1 = Mild; Grade 2 = Moderate; Grade 3 = Severe; Grade 4 = Potentially Life Threatening. Grade refers to the severity of the AEs. Treatment period was defined as the time from the first dose of study treatments up to 30 days after last dose of study treatment. Participants with Grade 3 and 4 liver function abnormalities were reported in this outcome measure.
Query!
Timepoint [16]
0
0
From first dose of study treatment up to 30 days after last dose of study treatment (maximum duration: 112 weeks)
Query!
Eligibility
Key inclusion criteria
Inclusion criteria :
- Adult participants with loco-regional recurrent or metastatic disease not amenable to
curative treatment.
- Confirmed diagnosis of ER+/HER2- breast cancer.
- No prior systemic treatment for loco-regional recurrent or metastatic disease.
- Measurable disease evaluable per Response Evaluation Criterion in Solid Tumors
(RECIST) v.1.1 or non-measurable bone-only disease.
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
- Participants should be willing to provide tumor tissue.
- Capable of giving informed consent.
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion criteria:
- Known active brain metastases.
- Prior neo (adjuvant) treatment with any selective estrogen receptor degrader (SERD).
- Inadequate organ and marrow function.
- Disease recurrence while on, or within 12 months of completion of (neo)adjuvant
endocrine therapy.
- Pregnant, breastfeeding, or woman of childbearing potential unwilling to use
recommended contraception methods.
- Male participants who disagree to follow contraception.
- Participants with advanced, symptomatic visceral spread, that are at risk of
life-threatening complications in the short term.
- Participants with significant concomitant illness.
The above information was not intended to contain all considerations relevant to a
participant's potential participation in a clinical trial.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Blinded (masking used)
Query!
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Terminated
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
14/10/2020
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
26/05/2023
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
1068
Query!
Recruitment in Australia
Recruitment state(s)
NSW,VIC,WA
Query!
Recruitment hospital [1]
0
0
Investigational Site Number :0360004 - Macquarie Park
Query!
Recruitment hospital [2]
0
0
Investigational Site Number :0360005 - Randwick
Query!
Recruitment hospital [3]
0
0
Investigational Site Number :0360003 - Wahroonga
Query!
Recruitment hospital [4]
0
0
Investigational Site Number :0360002 - Richmond
Query!
Recruitment hospital [5]
0
0
Investigational Site Number :0360001 - Nedlands
Query!
Recruitment postcode(s) [1]
0
0
2109 - Macquarie Park
Query!
Recruitment postcode(s) [2]
0
0
2031 - Randwick
Query!
Recruitment postcode(s) [3]
0
0
2076 - Wahroonga
Query!
Recruitment postcode(s) [4]
0
0
3121 - Richmond
Query!
Recruitment postcode(s) [5]
0
0
6009 - Nedlands
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Illinois
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Indiana
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Iowa
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kansas
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maine
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Massachusetts
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Michigan
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Missouri
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nevada
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Jersey
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New York
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
North Carolina
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
Oregon
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Pennsylvania
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Texas
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
Virginia
Query!
Country [23]
0
0
Argentina
Query!
State/province [23]
0
0
Buenos Aires
Query!
Country [24]
0
0
Argentina
Query!
State/province [24]
0
0
Córdoba
Query!
Country [25]
0
0
Argentina
Query!
State/province [25]
0
0
Santa Fe
Query!
Country [26]
0
0
Argentina
Query!
State/province [26]
0
0
La Rioja
Query!
Country [27]
0
0
Argentina
Query!
State/province [27]
0
0
Mar del Plata
Query!
Country [28]
0
0
Argentina
Query!
State/province [28]
0
0
Salta
Query!
Country [29]
0
0
Austria
Query!
State/province [29]
0
0
Graz
Query!
Country [30]
0
0
Belgium
Query!
State/province [30]
0
0
Bruxelles
Query!
Country [31]
0
0
Belgium
Query!
State/province [31]
0
0
Charleroi
Query!
Country [32]
0
0
Belgium
Query!
State/province [32]
0
0
Leuven
Query!
Country [33]
0
0
Belgium
Query!
State/province [33]
0
0
Namur
Query!
Country [34]
0
0
Brazil
Query!
State/province [34]
0
0
Rio Grande Do Sul
Query!
Country [35]
0
0
Brazil
Query!
State/province [35]
0
0
São Paulo
Query!
Country [36]
0
0
Brazil
Query!
State/province [36]
0
0
Rio De Janeiro
Query!
Country [37]
0
0
Bulgaria
Query!
State/province [37]
0
0
Burgas
Query!
Country [38]
0
0
Bulgaria
Query!
State/province [38]
0
0
Dobrich
Query!
Country [39]
0
0
Bulgaria
Query!
State/province [39]
0
0
Russe
Query!
Country [40]
0
0
Bulgaria
Query!
State/province [40]
0
0
Sofia
Query!
Country [41]
0
0
Canada
Query!
State/province [41]
0
0
Ontario
Query!
Country [42]
0
0
Canada
Query!
State/province [42]
0
0
Quebec
Query!
Country [43]
0
0
Chile
Query!
State/province [43]
0
0
Coquimbo
Query!
Country [44]
0
0
Chile
Query!
State/province [44]
0
0
La Araucanía
Query!
Country [45]
0
0
Chile
Query!
State/province [45]
0
0
Maule
Query!
Country [46]
0
0
Chile
Query!
State/province [46]
0
0
Reg Metropolitana De Santiago
Query!
Country [47]
0
0
Chile
Query!
State/province [47]
0
0
Valparaíso
Query!
Country [48]
0
0
Chile
Query!
State/province [48]
0
0
Santiago de Chile
Query!
Country [49]
0
0
Chile
Query!
State/province [49]
0
0
Santiago
Query!
Country [50]
0
0
China
Query!
State/province [50]
0
0
Baoding
Query!
Country [51]
0
0
China
Query!
State/province [51]
0
0
Beijing
Query!
Country [52]
0
0
China
Query!
State/province [52]
0
0
Changchun
Query!
Country [53]
0
0
China
Query!
State/province [53]
0
0
Chengdu
Query!
Country [54]
0
0
China
Query!
State/province [54]
0
0
Chongqing
Query!
Country [55]
0
0
China
Query!
State/province [55]
0
0
Dalian
Query!
Country [56]
0
0
China
Query!
State/province [56]
0
0
Deyang
Query!
Country [57]
0
0
China
Query!
State/province [57]
0
0
Fuzhou
Query!
Country [58]
0
0
China
Query!
State/province [58]
0
0
Guangzhou
Query!
Country [59]
0
0
China
Query!
State/province [59]
0
0
Hangzhou
Query!
Country [60]
0
0
China
Query!
State/province [60]
0
0
Harbin
Query!
Country [61]
0
0
China
Query!
State/province [61]
0
0
Hefei
Query!
Country [62]
0
0
China
Query!
State/province [62]
0
0
Jinan
Query!
Country [63]
0
0
China
Query!
State/province [63]
0
0
Jining
Query!
Country [64]
0
0
China
Query!
State/province [64]
0
0
Linyi
Query!
Country [65]
0
0
China
Query!
State/province [65]
0
0
Luoyang
Query!
Country [66]
0
0
China
Query!
State/province [66]
0
0
Neijiang
Query!
Country [67]
0
0
China
Query!
State/province [67]
0
0
Shanghai
Query!
Country [68]
0
0
China
Query!
State/province [68]
0
0
Shaoguan
Query!
Country [69]
0
0
China
Query!
State/province [69]
0
0
Tianjin
Query!
Country [70]
0
0
China
Query!
State/province [70]
0
0
Wuhan
Query!
Country [71]
0
0
China
Query!
State/province [71]
0
0
Xi'an
Query!
Country [72]
0
0
China
Query!
State/province [72]
0
0
Xi'An
Query!
Country [73]
0
0
China
Query!
State/province [73]
0
0
Xuzhou
Query!
Country [74]
0
0
China
Query!
State/province [74]
0
0
Yantai
Query!
Country [75]
0
0
China
Query!
State/province [75]
0
0
Zhengzhou
Query!
Country [76]
0
0
Czechia
Query!
State/province [76]
0
0
Brno
Query!
Country [77]
0
0
Czechia
Query!
State/province [77]
0
0
Praha 2
Query!
Country [78]
0
0
Finland
Query!
State/province [78]
0
0
Helsinki
Query!
Country [79]
0
0
Finland
Query!
State/province [79]
0
0
Tampere
Query!
Country [80]
0
0
Finland
Query!
State/province [80]
0
0
Turku
Query!
Country [81]
0
0
France
Query!
State/province [81]
0
0
Nice
Query!
Country [82]
0
0
France
Query!
State/province [82]
0
0
Paris
Query!
Country [83]
0
0
France
Query!
State/province [83]
0
0
Poitiers
Query!
Country [84]
0
0
France
Query!
State/province [84]
0
0
Saint Cloud
Query!
Country [85]
0
0
France
Query!
State/province [85]
0
0
Saint-Herblain
Query!
Country [86]
0
0
France
Query!
State/province [86]
0
0
Strasbourg
Query!
Country [87]
0
0
France
Query!
State/province [87]
0
0
TOULOUSE Cedex 9
Query!
Country [88]
0
0
France
Query!
State/province [88]
0
0
Villejuif
Query!
Country [89]
0
0
Georgia
Query!
State/province [89]
0
0
Batumi
Query!
Country [90]
0
0
Georgia
Query!
State/province [90]
0
0
Kutaisi
Query!
Country [91]
0
0
Georgia
Query!
State/province [91]
0
0
Tbilisi
Query!
Country [92]
0
0
Germany
Query!
State/province [92]
0
0
Bottrop
Query!
Country [93]
0
0
Germany
Query!
State/province [93]
0
0
Münster
Query!
Country [94]
0
0
Germany
Query!
State/province [94]
0
0
Oldenburg in Holstein
Query!
Country [95]
0
0
Germany
Query!
State/province [95]
0
0
Ulm
Query!
Country [96]
0
0
Hungary
Query!
State/province [96]
0
0
Budapest
Query!
Country [97]
0
0
Hungary
Query!
State/province [97]
0
0
Gyula
Query!
Country [98]
0
0
Hungary
Query!
State/province [98]
0
0
Gyor
Query!
Country [99]
0
0
Hungary
Query!
State/province [99]
0
0
Kaposvár
Query!
Country [100]
0
0
Hungary
Query!
State/province [100]
0
0
Kecskemét
Query!
Country [101]
0
0
Hungary
Query!
State/province [101]
0
0
Miskolc
Query!
Country [102]
0
0
Hungary
Query!
State/province [102]
0
0
Nyíregyháza
Query!
Country [103]
0
0
Italy
Query!
State/province [103]
0
0
Emilia-Romagna
Query!
Country [104]
0
0
Italy
Query!
State/province [104]
0
0
Milano
Query!
Country [105]
0
0
Italy
Query!
State/province [105]
0
0
Monza E Brianza
Query!
Country [106]
0
0
Italy
Query!
State/province [106]
0
0
Bologna
Query!
Country [107]
0
0
Italy
Query!
State/province [107]
0
0
Napoli
Query!
Country [108]
0
0
Italy
Query!
State/province [108]
0
0
Prato
Query!
Country [109]
0
0
Japan
Query!
State/province [109]
0
0
Aichi
Query!
Country [110]
0
0
Japan
Query!
State/province [110]
0
0
Chiba
Query!
Country [111]
0
0
Japan
Query!
State/province [111]
0
0
Ehime
Query!
Country [112]
0
0
Japan
Query!
State/province [112]
0
0
Fukuoka
Query!
Country [113]
0
0
Japan
Query!
State/province [113]
0
0
Gunma
Query!
Country [114]
0
0
Japan
Query!
State/province [114]
0
0
Hiroshima
Query!
Country [115]
0
0
Japan
Query!
State/province [115]
0
0
Hokkaido
Query!
Country [116]
0
0
Japan
Query!
State/province [116]
0
0
Kagoshima
Query!
Country [117]
0
0
Japan
Query!
State/province [117]
0
0
Kanagawa
Query!
Country [118]
0
0
Japan
Query!
State/province [118]
0
0
Miyagi
Query!
Country [119]
0
0
Japan
Query!
State/province [119]
0
0
Miyazaki
Query!
Country [120]
0
0
Japan
Query!
State/province [120]
0
0
Osaka
Query!
Country [121]
0
0
Japan
Query!
State/province [121]
0
0
Saitama
Query!
Country [122]
0
0
Japan
Query!
State/province [122]
0
0
Shizuoka
Query!
Country [123]
0
0
Japan
Query!
State/province [123]
0
0
Tokyo
Query!
Country [124]
0
0
Korea, Republic of
Query!
State/province [124]
0
0
Gyeonggi-do
Query!
Country [125]
0
0
Korea, Republic of
Query!
State/province [125]
0
0
Seoul-teukbyeolsi
Query!
Country [126]
0
0
Korea, Republic of
Query!
State/province [126]
0
0
Seochogu
Query!
Country [127]
0
0
Korea, Republic of
Query!
State/province [127]
0
0
Seongnam-si, Gyeonggi-do
Query!
Country [128]
0
0
Netherlands
Query!
State/province [128]
0
0
Arnhem
Query!
Country [129]
0
0
Netherlands
Query!
State/province [129]
0
0
Delft
Query!
Country [130]
0
0
Netherlands
Query!
State/province [130]
0
0
Maastricht
Query!
Country [131]
0
0
Poland
Query!
State/province [131]
0
0
Lódzkie
Query!
Country [132]
0
0
Poland
Query!
State/province [132]
0
0
Wielkopolskie
Query!
Country [133]
0
0
Portugal
Query!
State/province [133]
0
0
Almada
Query!
Country [134]
0
0
Portugal
Query!
State/province [134]
0
0
Lisboa
Query!
Country [135]
0
0
Portugal
Query!
State/province [135]
0
0
Porto
Query!
Country [136]
0
0
Russian Federation
Query!
State/province [136]
0
0
Arkhangelsk
Query!
Country [137]
0
0
Russian Federation
Query!
State/province [137]
0
0
Krasnogorskiy District
Query!
Country [138]
0
0
Russian Federation
Query!
State/province [138]
0
0
Moscow Region
Query!
Country [139]
0
0
Russian Federation
Query!
State/province [139]
0
0
Moscow
Query!
Country [140]
0
0
Russian Federation
Query!
State/province [140]
0
0
Saint -Petersburg
Query!
Country [141]
0
0
Russian Federation
Query!
State/province [141]
0
0
Saint Petersburg
Query!
Country [142]
0
0
Singapore
Query!
State/province [142]
0
0
Singapore
Query!
Country [143]
0
0
South Africa
Query!
State/province [143]
0
0
Cape Town
Query!
Country [144]
0
0
South Africa
Query!
State/province [144]
0
0
Johannesburg
Query!
Country [145]
0
0
Spain
Query!
State/province [145]
0
0
Barcelona [Barcelona]
Query!
Country [146]
0
0
Spain
Query!
State/province [146]
0
0
Castilla Y León
Query!
Country [147]
0
0
Spain
Query!
State/province [147]
0
0
Galicia [Galicia]
Query!
Country [148]
0
0
Spain
Query!
State/province [148]
0
0
Madrid, Comunidad De
Query!
Country [149]
0
0
Spain
Query!
State/province [149]
0
0
Valenciana, Comunidad
Query!
Country [150]
0
0
Spain
Query!
State/province [150]
0
0
Madrid
Query!
Country [151]
0
0
Spain
Query!
State/province [151]
0
0
Málaga
Query!
Country [152]
0
0
Spain
Query!
State/province [152]
0
0
Valencia
Query!
Country [153]
0
0
Taiwan
Query!
State/province [153]
0
0
Kaohsiung
Query!
Country [154]
0
0
Taiwan
Query!
State/province [154]
0
0
Tainan
Query!
Country [155]
0
0
Taiwan
Query!
State/province [155]
0
0
Taipei
Query!
Country [156]
0
0
Turkey
Query!
State/province [156]
0
0
Adana
Query!
Country [157]
0
0
Turkey
Query!
State/province [157]
0
0
Ankara
Query!
Country [158]
0
0
Turkey
Query!
State/province [158]
0
0
Antalya
Query!
Country [159]
0
0
Turkey
Query!
State/province [159]
0
0
Bornova
Query!
Country [160]
0
0
Turkey
Query!
State/province [160]
0
0
Diyarbakir
Query!
Country [161]
0
0
Turkey
Query!
State/province [161]
0
0
Edirne
Query!
Country [162]
0
0
Turkey
Query!
State/province [162]
0
0
Istanbul
Query!
Country [163]
0
0
Turkey
Query!
State/province [163]
0
0
Izmir
Query!
Country [164]
0
0
Turkey
Query!
State/province [164]
0
0
Kocaeli
Query!
Country [165]
0
0
Turkey
Query!
State/province [165]
0
0
Malatya
Query!
Country [166]
0
0
Ukraine
Query!
State/province [166]
0
0
Kharkiv
Query!
Country [167]
0
0
Ukraine
Query!
State/province [167]
0
0
Kryvyi Rih
Query!
Country [168]
0
0
Ukraine
Query!
State/province [168]
0
0
Odesa
Query!
Country [169]
0
0
Ukraine
Query!
State/province [169]
0
0
Vinnytsia
Query!
Country [170]
0
0
United Kingdom
Query!
State/province [170]
0
0
Central Bedfordshire
Query!
Country [171]
0
0
United Kingdom
Query!
State/province [171]
0
0
Edinburgh, City Of
Query!
Country [172]
0
0
United Kingdom
Query!
State/province [172]
0
0
Lancashire
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Sanofi
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Primary Objective:
To determine whether Amcenestrant (SAR439859) in combination with palbociclib improves
progression free survival (PFS) when compared with letrozole in combination with palbociclib
in participants with estrogen receptor positive (ER+), human epidermal growth factor receptor
2 negative (HER2-) advanced breast cancer who have not received any prior systemic anticancer
therapies for advanced disease.
Secondary Objective:
- To compare the overall survival in both treatment arms.
- To evaluate the objective response rate in both treatment arms.
- To evaluate the duration of response in both treatment arms.
- To evaluate the clinical benefit rate in both treatment arms.
- To evaluate progression-free survival on next line of therapy.
- To evaluate the pharmacokinetics of amcenestrant, and palbociclib.
- To evaluate health-related quality of life in both treatment arms.
- To evaluate the time to first chemotherapy in both treatment arms.
- To evaluate safety in both treatment arms.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT04478266
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Clinical Sciences & Operations
Query!
Address
0
0
Sanofi
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT04478266
Download to PDF